Respiratory Distress Syndrome (RDS)

Also known as: Respiratory Distress Syndrome / Distress respiratory syndrome adults / Hyaline membrane disease / Shock lung / Syndrome adult respiratory distress / Syndrome respiratory distress adult / Respiratory distress syndrome adult / Acute respiratory distress syndrome in adult or child / Acute respiratory distress syndrome / Syndrome adult respiratory / A.R.D.S. / Adult respiratory distress syndr / Adult respiratory stress syndrome / ARDS / Adult respiratory distress syndrome / Respiratory Distress Syndrome, Adult / Adult RDS

DrugDrug NameDrug Description
DB06761BeractantBeractant is a pulmonary surfactant used for the treatment of Respiratory Distress Syndrome (RDS) in premature infants. Considered a natural source of surfactant as it is made from bovine lung extract, beractant contains a mixture of phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins such as SP-B and SP-C. The final composition provides 25 mg/mL phospholipids (including 11.0-15.5 mg/mL disaturated phosphatidylcholine), 0.5-1.75 mg/mL triglycerides, 1.4-3.5 mg/mL free fatty acids, and less than 1.0 mg/mL protein. It is suspended in 0.9% sodium chloride solution, and heat-sterilized. In anticipation of birth, endogenous lung surfactant is produced to lower the surface tension on alveolar surfaces and to stabilize the alveoli against collapse at resting transpulmonary pressures. However, in Respiratory Distress Syndrome, developmental deficiency of surfactant results collapse of the alveoli causing fast breathing, increased heart rate, apoxia, and sometimes death. Administration of lung surfactant remains the cornerstone of therapy in this condition that is currently the leading cause of death in preterm infants. In comparison to synthetic forms of surfacant, natural forms such as Beractant have been found to have a reduced incidence of pneumothorax and reduced mortality.
DB06415CalfactantCalfactant is a sterile, non-pyrogenic lung surfactant intended for intratracheal instillation. It is an off-white suspension of an extract of natural surfactant from calf lungs suspended in 0.9% saline. Each milliliter of calfactant contains 35mg of phospholipids (including 26 mg phosphatidylcholine of which 16 mg is disaturated phosphatidylcholine) and 0.65mg of proteins including surfactant-associated proteins B and C. Calfactant is approved for use in the United States of America. It is used to prevent or treat respiratory distress syndrome in premature infants with lung surfactant deficiency. Calfactant has been shown to decrease the incidence of respiratory distress syndrome, mortality due to respiratory distress syndrome, and air leaks associated with respiratory distress syndrome in clinical trials. It adsorbs to the air:fluid interface in the lungs and works to reduce surface tension, in a manner similar to endogenous pulmonary surfactant.
DB09113Poractant alfaPoractant alfa is a pulmonary surfactant marketed as Curosurf in the United States and Canada. It is used to treat Respiratory Distress Syndrome (RDS) in premature infants with an endogenous pulmonary surfactant deficiency. Poractant alfa is an extract of natural porcine lung surfactant consisting of 99% polar lipids (mainly phospholipids) and 1% hydrophobic low molecular weight proteins (surfactant associated proteins SP-B and SP-C). The phospholipid content of the extract consists primarily of phosphatidylcholine and dipaImitoylphosphatidylcholine. Poractant alfa is a creamy white suspension of this extract in 0.9% sodium chloride solution. It contains no preservatives.
DrugDrug NameTargetType
DrugDrug NamePhaseStatusCount
DB00572Atropine1Not Yet Recruiting1
DB00813Fentanyl1Not Yet Recruiting1
DB02772Sucrose1Not Yet Recruiting1
DB04897Lucinactant2Terminated1
DB00316Acetaminophen2 / 3Recruiting1
DB06761Beractant2 / 3Not Yet Recruiting1
DB11121Chloroxylenol2 / 3Completed1
DB01050Ibuprofen2 / 3Recruiting1
DB06761Beractant3Terminated1
DB00443Betamethasone3Active Not Recruiting1
DB00443Betamethasone3Completed1
DB06415Calfactant3Completed2
DB01211Clarithromycin3Recruiting1
DB01234Dexamethasone3Completed2
DB01234Dexamethasone3Terminated1
DB09113Poractant alfa3Completed1
DB09153Sodium chloride3Terminated1
DB09145Water3Recruiting1
DB06761Beractant4Completed1
DB06761Beractant4Terminated1
DB06761Beractant4Unknown Status1
DB01222Budesonide4Not Yet Recruiting1
DB01222Budesonide4Recruiting1
DB01222Budesonide4Unknown Status1
DB09337Medical air4Unknown Status1
DB09152Nitrogen4Unknown Status1
DB09140Oxygen4Unknown Status1
DB09113Poractant alfa4Recruiting1
DB09113Poractant alfa4Terminated1
DB00818Propofol4Unknown Status1
DB00899Remifentanil4Completed1
DB00728Rocuronium4Completed1
DB09153Sodium chloride4Not Yet Recruiting1
DB09153Sodium chloride4Recruiting1
DB06761BeractantNot AvailableWithdrawn1
DB00443BetamethasoneNot AvailableCompleted1
DB01222BudesonideNot AvailableCompleted1
DB06415CalfactantNot AvailableCompleted3
DB01234DexamethasoneNot AvailableCompleted1
DB01088IloprostNot AvailableWithdrawn1
DB09113Poractant alfaNot AvailableActive Not Recruiting1
DB09113Poractant alfaNot AvailableCompleted2
DB09113Poractant alfaNot AvailableWithdrawn1